New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It [Yahoo! Finance]
New Clinical Evidence on Hologic’s AI-Powered Mammography Solutions Will Be Unveiled at RSNA
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOLX, MOFG, NIC, and AWK
Hologic (NASDAQ:HOLX) was downgraded by analysts at BNP Paribas Exane from an "outperform" rating to a "neutral" rating. They now have a $79.00 price target on the stock.